Repaglinide–Metformin Tablets | Antidiabetic Combination

Therapeutic Indication

Type 2 Diabetes Mellitus (when diet, exercise, or monotherapy is insufficient)

+91 85919 78885

Repaglinide + Metformin

Tablet

Repaglinide–Metformin tablets combine a meglitinide (Repaglinide) that stimulates insulin release and a biguanide (Metformin) that reduces hepatic glucose production and improves insulin sensitivity.

Speciality	Endocrinology \| Diabetology
Tags	Type 2 Diabetes \| Oral Antidiabetic \| Combination Therapy
Strength	Repaglinide 1 mg/li> Metformin 500 mg
Packing Size	10 Tablets

Check all Tablet Range

Click to know More

Mechanism

Repaglinide stimulates insulin release from pancreatic beta cells by closing ATP-dependent potassium channels. Metformin decreases hepatic glucose production, increases peripheral glucose uptake, and reduces intestinal glucose absorption.

Pharmacokinetics

Absorption: Rapid oral absorption.
Metabolism: Repaglinide via CYP3A4; Metformin not metabolized.
Excretion: Repaglinide via bile; Metformin via urine.
Half-life: Repaglinide ~1 hour; Metformin ~6 hours.

Side Effects

Hypoglycemia
Weight gain
Gastrointestinal upset (nausea, diarrhea)
Headache

Contraindication

Type 1 Diabetes Mellitus
Diabetic ketoacidosis
Severe renal impairment (eGFR <30 mL/min/1.73 m²)
Hepatic impairment

Interaction

Gemfibrozil (increases repaglinide levels → hypoglycemia)
Alcohol (risk of lactic acidosis with metformin)
Beta-blockers (mask hypoglycemia symptoms)
CYP3A4 inhibitors (clarithromycin, ketoconazole → ↑ repaglinide)

Warning and Precautions

Use under medical supervision only
Monitor renal function before and during therapy
Discontinue if lactic acidosis is suspected
Advise patients to avoid excessive alcohol intake

Dosage

As directed by the Physician.